Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

India’s Micro Therapeutic says EMA’s ‘Sweep’ Suspension Will Hurt; CRO Industry Shuns ‘Bad Eggs’

Data integrity concerns continue to cloud outlook for India’s contract research sector. The European Medicines Agency’s latest action against Micro Therapeutic Research Labs suspends more than 300 products in the EU over “unreliable” data and the firm tells Pink Sheet this will result in a “considerable dent” in its operations.

Policy & Regulation Regulation

India Eases Approval Process For HIV, Hepatitis Combinations

India has outlined measures to fast track the regulatory process for certain combination products for HIV and hepatitis, and thereby facilitate early access to these treatments.

Review Pathway Infectious Diseases

Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones

Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.

Commercial Deals

South East Asia Steps Up Fight Against TB

South East Asia is gearing for additional momentum in the fight against TB, a disease that caused nearly 800,000 deaths in the region in 2015. Increased budgetary outlays, a regional “Innovation to Implementation” fund and the need for high impact interventions were among the key issues brought up at a recent ministerial meeting in India.

Infectious Diseases Market Access

FDA To Lift Ban On Ranbaxy Plant; Good News For Sun Compliance Push?

A US FDA ban on Sun Pharma’s Mohali site, a legacy Ranbaxy facility, is set to be lifted, marking a significant uptick in Sun’s compliance efforts and raising hopes of momentum at the Indian firm’s other tainted facilities.

Manufacturing India

Mylan Revamp Sees India R&D Layoffs; More In Store?

Mylan has handed pink slips to around 50 personnel at its Indian R&D unit as it pursues a global revamp aimed at streamlining operations and reining in costs following multiple acquisitions over the past few years.

Commercial India
See All
Advertisement
UsernamePublicRestriction

Register